Taking your program from early-phase clinical trials through real-world evidence, with the reach of a large CRO and the responsiveness of a mid-size partner who knows your science.
Learn More About Us
The prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read moreThe prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read more
Our team recently attended two leading forums focused on the future of MASH research and treatment: the 2026 Paris MASH Meeting and the 10th MASH Drug Development Summit in Boston. Together, the conferences brought perspectives from clinical pract...
For people experiencing changes in memory and thinking, and for those who support them, an Alzheimer’s diagnosis can bring difficult questions about independence, treatment, and the future. It can also provide a starting point for informed decis...
How sponsors can recognize material underperformance, diagnose root causes, and select the least disruptive path to recovery. Clinical trials rarely move from “on track” to “in crisis” overnight. Warning signs usually emerge gradually: si...
"*" indicates required fields
"*" indicates required fields
